

# GRIFOLS

## **Grifols appoints Shanghai RAAS exclusive distributor of its NAT solutions in China**

Grifols and Shanghai RAAS (SRAAS) have taken another step in the roll out of their strategic alliance, designating Anhui Tonrol of the SRAAS Group as the exclusive distributor of Grifols' leading nucleic acid technology (NAT) portfolio in the country.

The move, effective on April 15, 2022, combines the heritage, renown and leadership of SRAAS in China's blood products industry with the expertise, experience and global leadership of Grifols in blood and plasma screening and safety, as well as transfusion medicine.

SRAAS will import, distribute and commercialize Grifols' NAT platform based on TMA (transcription-mediated amplification), a highly sensitive molecular test for blood and plasma screening to detect viruses such as HIV-1, HIV-2, HCV and HBV (subject to scope approval by the authorities).

This molecular test, commercialized under the Procleix® brand, is part of a comprehensive NAT screening solution that also includes Grifols' Procleix® Panther System, which integrates full automation with versatility and smart operations for efficient NAT processing of blood and plasma within a very compact footprint.

SRAAS will carry out all related sales and marketing activities on the Chinese Mainland—except for Taiwan, Hong Kong and Macau – as well as provide preinstallation, installation and technical support to customers.

SRAAS holds a leading position in China's blood products Industry, with four manufacturing sites and 41 plasma centers across 11 provinces. In 1999, it was the first company to adopt NAT testing, which it conducts three separate times during the process to collect plasma and manufacture hemoderivatives.

In 2020, NAT tested more than 15 million blood donations in China, a screening process that Chinese health authorities are also extending to the more than 15 million plasma donations collected each year in the country. This is in addition to mandatory serology tests.

A transition period of 6-to-12 months will allow SRAAS to receive all necessary authorizations, procedures and permits, enabling a seamless NAT distribution transition.

With this strategic move, Grifols and SRAAS will relaunch the Grifols NAT product in China and work together to become a key player in the country.

Grifols is a leader in transfusion safety. Its Procleix® Panther System is one of the most widely used platforms globally to screen blood donations.